Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotechwantabe who wrote (3500)	4/27/2023 10:33:01 AM
From: DewDiligence_on_SI	Respond to of 3557

Vabismo is already selling at a $2B annualized rate. Roche considers Vabismo to be the strongest growth driver in the company’s entire portfolio. investorshub.advfn.com

To: Biotechwantabe who wrote (3500)	4/27/2023 6:54:34 PM
From: A.J. Mullen	Respond to of 3557

Q1 Roche Zabysmo doing well +432. Does it impact Eylea growth? Probably what’s scaring the market. What's your thinking (or anyone else's) with respect to Unity's threat to Eylea? ir.unitybiotechnology.com. They're planning a head to head trial against Eylea in diabetic macular edema. It's a smaller market than wet AMD. Unity failed in a trial against Eylea in wet AMD earlier this month, but they don't seem to have given up on that indication. They're partnered with Astrazeneca. Ashley

To: Biotechwantabe who wrote (3500)	5/4/2023 11:09:00 AM
From: A.J. Mullen	Read Replies (1) \| Respond to of 3557

Looks like the market was correct to worry about Vabysmo, investors.com